Public Health Emergency - Leading a Nation Prepared
All dialysis centers can provide monoclonal antibody (mAb) therapy for non-hospitalized patients who have tested positive for COVID-19 and have mild to moderate symptoms. These treatments are indicated for eligible patients 12 years and older with a high risk of progressing to severe forms of COVID-19 or being hospitalized.Dialysis centers are able to order casirivimab/imdevimab and bamlanivimab/etesevimab monoclonal antibodies for their facilities. The administration of these COVID-19 therapeutics requires intravenous infusion.
If you are considering having your dialysis center offer COVID-19 mAb therapy, you can quickly evaluate your readiness in three steps:
Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language
Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201
U.S. Department of Health and Human Services | USA.gov |
HealthCare.gov in Other Languages